CanadaBis Capital Inc. (TSXV:CANB) (“CanadaBis” or “the Company”) a holder of a federal licence to cultivate and process under the Cannabis Act, is pleased to announce that on March 6th, 2020, its subsidiary 1998643 AB LTD. (“Stigma Grow”) secured its licence from Health Canada to sell cannabis cultivated at its 66,000 square foot cultivation facility in Red Deer, Alberta.

canadabis stigma grow


Stigma Grow – Cannabis grown by Albertans, for Albertans

Securing their sales licence for dry flower represents a huge milestone along the way to achieving their vision as a well-positioned, multi-pillared cannabis company, and will act as the cornerstone for several brands within the CanadaBis’ family of brands as they continue to grow in multiple areas; keenly seeking out new partnerships and opportunities to provide value to their industry and stakeholders.
“We are thrilled to secure approval to begin selling our high-quality cannabis,” said Travis McIntyre, CEO of CanadaBis Capital Inc. “We are now perfectly positioned to grow and sell dry flower that will be among the highest potency available today, which is important when you consider what’s lacking in the current market and what’s needed to ensure the future of legal cannabis remains bright” said President & CEO, Travis McIntyre.

The Company anticipates a shift in consumer behaviour from a focus on dry flower to a focus on concentrates in 2020 and beyond. To prepare for this demand, the Company has spent six months perfecting their systems and constructing a CIDI Lab to house hydrocarbon extraction processing — positioning them to bring difficult-to-produce products to market on a mass scale.

“We’re just getting started! Stigma Grow intends to leverage our own top-quality flower, state-of-the-art technology, and the insight provided by our skilled and experienced staff, to target consumers and partner LPs looking for high-quality, ‘bud-run’ extract product variations”, explains Travis. “Our vision as a company has always been to provide our community with what is in-demand, and all signs point to the need for consistent, high-potency concentrates.”

While the Company awaits the final stages of their revised sales licence to include concentrates – they are actively stockpiling products to meet demands that will likely surpass supply for many years.

About Stigma Grow’s Red Deer Cultivation and Processing Facility

Cultivation
Although the Company sees a shift in focus from flower to concentrates, they have not lost sight of the need to provide high-quality craft cannabis, and recognize the synergistic connection.

As with any Premium Product, the best inputs generate the best outputs. The combination of the two sets the stage for our long-term plans as a craft-cannabis cultivator recognized for high-quality in everything we produce. This ongoing commitment to both sides of the cannabis market will allow us to control the quality of our products, and always ensure an optimized offering.

Stigma Grow currently operates 22,000 sq/ft of production space and is in the midst of their Phase 2 expansion which will increase this area to 66,000 sq/ft by mid-2020. Proudly offering craft-quality products with optimal cannabinoid profiles, Stigma Grow was the first Health Canada-licenced producer operating in the Red Deer area.

Processing

In addition to representing products that are in high demand, Stigma concentrate products will be some of the first available in the Canadian legal market.

Stigma’s concentrates promise an extremely clean, consistent and pure form of cannabis product, and Stigma’s third-party processing abilities have already captured the interest of several LPs looking for service providers capable of facilitating the expansion of their own lines of products.

At present, Stigma has signed agreements with several reputable LPs to conduct concentrate manufacturing on their behalf, and currently hold POs for provincial channels scheduled for a second-quarter delivery of high-quality, terpene-rich, badder, live res badder and live res caviar.

The Company is currently in talks for multiple synergistic partnerships, and expects to make another announcement in the coming weeks.

For more information, access the Company’s investor presentation and recently updated strategic direction at their website: CanadaBis.com

About CanadaBis Capital Inc.

CanadaBis Capital Inc. (TSXV: CANB) is a vertically integrated Canadian cannabis company focused on achieving large-scale growth in the fast-emerging global cannabis market. By targeting organic growth opportunities alongside the right-fit partners, we remain focused on finding and capitalizing on chances to grow, diversify and continue to lead our industry.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to our business and operations including development and expansion plans; intention to develop property in British Columbia; increasing our product lines to include CBD distillates; and our general business plans. Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: compliance with extensive government regulation, the general business, economic, competitive, political and social uncertainties; successful negotiation of necessary agreements to get our product to market; requirement for further capital, delay or failure to receive board, shareholder or regulatory approvals; the results of operations and such other matters as set out in the Filing Statement available on SEDAR at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Accordingly, readers should not place undue reliance on forward-looking statements. Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although we believe that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have a material adverse effect on our future results, performance or achievements.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. CanadaBis Capital does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Click here to connect with CanadaBis Capital Inc. (TSXV:CANB) for an Investor Presentation

Source

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Zelira TherapeuticsLtd (ASX:ZLD,OTCQB:ZLDAF), a global leader in the research and development of clinically validated cannabinoid medicines, is pleased to announce that it has raised a total of US$5 million from Quincy Street Capital LLC (Quincy Street), a US-based family office fund, comprising:

  • US$3.5 million (A$4.79 million) via a placement of 79,908,676 Zelira fully paid ordinary shares at A$0.06 per share (Placement), a 54% premium to the stock’s last closing price
  • 1 unlisted option for every 2 ordinary shares issued, expiring 2 years from the date of issue with an exercise price of A$0.09 per option, with 39,954,338 total unlisted options to be issued
  • US$1.5 million (A$2.05 million) via an equity investment in Ilera Derm LLC (ZeliraDermatology) for a 3% shareholding in that company, valuing Zelira Dermatology at US$50 million.
Keep reading... Show less

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement (the ” Offering “). Under the Offering, the Company has issued an aggregate of 4,587,022 units (the ” Units “) at a price of CAD$0.85 per Unit for aggregate gross proceeds of approximately CAD$3.9 million.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf”, “OILS”, or the “Company”), a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids, is pleased to announce the Company has entered into a supply agreement with Quebec-based licensed producer Medicibis (“Mendo”) to supply its medical platform www.Mendocannabis.ca with Glacial Gold™ branded products.

Mendo operates an online portal for medical patients that ships nationwide through www.Mendocannabis.ca. Glacial Gold™ CBD and THC vapes and distilled oils will be distributed by Mendo to their medical cannabis clients in Quebec and across Canada.

Quebec is the third-largest cannabis market in Canada, representing approximately 15%[1] of Canadian cannabis retail sales in the country, and approximately 22% of the Canadian population[2].

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5347/100149_54a84d0cc4d15940_001.jpg
Figure 1: Glacial Gold CBD and THC Vapes and Distilled Oils

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/5347/100149_54a84d0cc4d15940_001full.jpg

Canadian spending on medical cannabis totaled $587 million in 2020[3]. Medical cannabis has become an important component of Canadian healthcare, with $119 million of medical cannabis purchases reimbursed by the Federal Government through Veterans Affairs Canada in 2020[4]. Despite Canada’s progressive cannabis regulation, price is still a major barrier for many medical patients.

Nextleaf leverages its patented high-efficiency ingredient processing technology to gain a competitive advantage and improve cannabis oil economics through the low-cost production of cannabis distillate standardized for potency and purity.

“Launching accessibly priced Glacial Gold™ vapes and distilled oils in Canada’s medical market and in Quebec have been important milestones for Nextleaf. We believe Mendo and their Quebec-based medical platform is positioned to become one of the leading suppliers of medical cannabis to patients and veterans in this country,” said Paul Pedersen, co-founder and CEO of Nextleaf Solutions. “Our innovative technology enables us to produce high purity ingredients at a low cost per molecule to offer patients quality CBD and THC products.”

“We are delighted to work with Nextleaf to offer Glacial Gold™ products through our recently expanded national portal, accessible by medical patients Canada-wide,” said Jay Schwartz, Director of Mendo Medical. “We are excited to feature the seven Glacial Gold™ SKUs that launched last month in British Columbia and to help them launch two new CBD SKUs that we think patients will be eager to experience.”

Nextleaf launched its award-winning, prohibition-era brand Glacial Gold™ in British Columbia last month, receiving national attention for quality products at disruptive price points. Included in the initial launch of Glacial Gold™ were seven total SKUs, consisting of four 1-gram vape SKUs and three distilled oil SKUs.

Glacial GoldDistilled CBD 50 Oil, Distilled THC 30 Oil, and Distilled 30:30 Blend feature high-purity distillate in a base of organic coconut MCT oil for a premium consumption experience, without premium pricing. A clean tasting and neutral oil allows for the greatest flexibility in use and consumption occasions.

The initial vape lineup from Glacial Gold is offered in two potency levels to match the consumer’s tolerance level or consumption occasion. The Session THC Vape features a full potency THC profile for cannabis enthusiasts who seek a more elevated experience and connection. The Anytime 1:1 Vape is formulated with a balanced THC and CBD profile for consumers looking for a more moderate, go-to vape.

About Medicibis

Medicibis is a federally licensed producer of dried cannabis and distributes its products under the brand name ENDO. Medicibis operates out of its 20,000 sq.ft. facility located 15 minutes from downtown Montreal in St Jean Sur Richelieu. Medicibis operates an online portal for medical patients that ships nationwide through their website mendocannabis.ca. Mendo’s menu has been carefully curated to offer a variety of products from licensed producers from all over Canada. Mendo is positioned to become one of the leading suppliers of medical cannabis to patients and veterans in the country.

About Nextleaf®

Nextleaf is a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids. Nextleaf distributes cannabis vapes and distilled oils under its award-winning prohibition-era brand, Glacial Gold™, and supplies cannabis distillate to its wholesale customers. Nextleaf’s proprietary closed-loop automated extraction plant in Metro Vancouver efficiently transforms cannabis and hemp grown in B.C. and throughout Canada into high-purity cannabis distillate at an industrial scale. Nextleaf is developing delivery technology and differentiated cannabinoid-based formulations through its Health Canada Research Licence with sensory evaluation of cannabis via human testing. The Company owns 17 U.S. patents and has been issued 95 patents globally.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow the Company across social platforms: Twitter, LinkedIn, Facebook, and Instagram.
www.nextleafsolutions.com

Follow Glacial Gold™ across social platforms: Instagram, Twitter, and Facebook. www.Glacial.Gold

For more information please contact:
Jason McBride, Corporate Development
604-283-2301 (ext. 219)
jason@nextleafsolutions.com

On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO

Certain statements contained in this press release constitute “forward-looking statements”. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company’s ability to capitalize on its IP portfolio, the Company’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.

Keep reading... Show less

Naturally Splendid Enterprises Ltd. (“Naturally Splendid“, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to announce the latest shipping container of NATERA Plant Based Foods from Australia has been received

In this shipment, we are excited to receive new SKUs including plant-based “Chick-Un Wings & Drumettes’ and a new Plant Based “Spicy Chick-Un Burger” that will be introduced to the Canadian Consumer. We also continue to receive more of our existing NATERA Plant Based Foods Breaded Cutlets (Schnitzel), Stuffed Chick-Un Breast (Garlic & Butter Flavoured), Sweet Chili Chick-Un Tenders, Seasoned Chick-Un Tenders, Chick-Un Nuggets, Chick-Un Patties, Crispy Fish-Un Fillets, Garlic Chick-Un Bites (Garlic & Butter Flavoured) and Cheesy Chick-Un Bites.

Keep reading... Show less

The ongoing volatility seen in the cannabis investment market has left one of the most promising areas in the entire space in a bind.

Executives and investment experts across the market told the Investing News Network (INN) in recent conversations that the current style of cannabis investing can’t support the goals of publicly traded medical cannabis researchers and drug makers.

Keep reading... Show less